Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
Jingchao Sun,Ying Xiao,Wenjie Xu,Wei Xing,Frank Du,Maozhi Tian,Danqi Xu,Yihua Ren,Xin Fang
DOI: https://doi.org/10.3389/fcvm.2024.1348897
IF: 3.6
2024-02-14
Frontiers in Cardiovascular Medicine
Abstract:Introduction: Angiotensin receptor-neprilysin inhibitor (ARNi), comprised of an angiotensin receptor blocker (ARB) and a neprilysin inhibitor (NEPi), has established itself as a safe and effective intervention for hypertension. S086 is a novel ARNi cocrystal developed by Salubris for the treatment of heart failure and hypertension. Methods: Dahl Salt Sensitive (DSS) hypertensive rat model and telemetry system were employed in this study to investigate the anti-hypertensive efficacy of S086 and compare it with the first ARNi-LCZ696. Results and discussion: The study showed that oral administration of S086 dose-dependently lowered blood pressure ( P < 0.001). The middle dosage of S086 (23 mg/kg) exhibited efficacy comparable to LCZ696 (68 mg/kg), while also demonstrating superiority at specific time points ( P < 0.05). Notably, water consumption slightly decreased post-treatment compared to the vehicle group. Furthermore, there were significant increases in natriuresis and diuresis observed on the first day of treatment with 23 mg/kg and 68 mg/kg S086 ( P < 0.001). However, over the course of treatment, the effects in all treatment groups gradually diminished. This study demonstrates the anti-hypertensive efficacy of S086 in DSS hypertensive rat model, offering promising avenues for the clinical development of S086 as a hypertension treatment. Graphical . Hypertension is a worldwide chronic cardiovascular disease (CVD) and the leading cause for premature death. Over the past few decades, the population of hypertension patients has surged due to the aging of society (1). According to data from the NCD (non-communicable diseases) Risk Factor Collaboration, there were more than 1.2 billion people aged 30–79 with hypertension worldwide in 2019, double the number from 1990 (2). Notably, the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Hypertension Guidelines have lowered the threshold for hypertension diagnosis from a systolic blood pressure (BP)/diastolic BP of ≥140/90 mm Hg to ≥130/80 mm Hg, indicating an increase in patients needing medical treatment in the future (3). High salt dietary consumption is one of the predominant risk factors for the essential pathogenesis of hypertension and strongly correlated with BP-independent organ damage. It has been reported that 30%–50% of hypertensive patients are associated with high salt intake (4). Studies suggest that high salt intake can lead to increased blood pressure by decreasing glomerular filtration membrane permeability, reducing filtration area and the number of glomeruli, and producing excess reactive oxygen species. As sodium load increases, endothelial function decreases, resulting in impaired vascular relaxation and elevated blood pressure (5, 6). Diuretics are effective in lowering blood pressure caused by a high-salt diet, but their adverse effects, such as low potassium and high uric acid, also require attention in clinics (7). ARNi, which is a co-crystal comprising an angiotensin receptor II blocker (ARB) and a neprilysin inhibitor (NEPi), is a novel therapy for cardiovascular disease (8). Its most common use in clinical practice is for heart failure patients, particularly those with reduced ejection fraction (HF-REF), and is recommended as the first-line therapy for HF-REF treatment by ACC (American College of Cardiology)/AHA (American Heart Association)/HFSA (Heart Failure Society of America) and ESC (European Society of Cardiology) guidelines (9, 10). Additionally, ARNi has shown efficacy in hypertensive patients due to NEPi's mechanism of inhibiting ANP (Atrial Natriuretic Peptide) and BNP (Brain natriuretic peptide) degradation which leads to natriuresis and diuresis, potentially reducing blood pressure in salt-sensitive patients (11). LCZ696 (Entresto) is the first ARNi product launched globally and has shown profound efficacy in controlling BP in Asian patients with salt-sensitive hypertension (12). In several clinical trials, LCZ696 had a significantly superior effect on BP control compared with current first-line antihypertensive agents, Valsartan, and Olmesartan (13–16). S086, a novel ARNi which is a co-crystal containing ARB (an active metabolite of Losartan), NEPi, calcium, and hydrate. EXP3174, which is a higher potency and longer t 1/2 ARB in S086 than Valsartan in LCZ696. The NEPi ingredient in S086 is the same as that in LCZ696, which is a prodrug of LBQ657-Sacubitril. S086 has been proven to have comparable efficacy to LCZ696 in rat and dog myocardial infarction models. Both S086 and LCZ696 improved the left ventricular ejection fraction and myocardial fibrosis, and do not have a significant impact on hemodynamics (17). The phase I clinical trial for S086 in healthy volunteers indicated a dose-dependent pharmacokinetic profile (C max and -Abstract Truncated-
cardiac & cardiovascular systems